Niagen Bioscience (NAGE) Non-Current Deffered Revenue (2011 - 2026)

Niagen Bioscience (NAGE) has reported Non-Current Deffered Revenue for 14 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue changed 0.27% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (changed 0.27% YoY), while the FY2025 annual figure was $2.7 million, up 2.85% from the prior year.
• Non-Current Deffered Revenue declined to $2.6 million in Q1 2026 per NAGE's latest filing, from $2.7 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $4.3 million in Q1 2022 and bottomed at $2.6 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $3.3 million across 5 years, with a median of $3.3 million in 2023.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue sank 32.24% — and 2025, when it grew 3.68%.
• Niagen Bioscience's Non-Current Deffered Revenue stood at $4.0 million in 2022, then slipped by 16.28% to $3.3 million in 2023, then retreated by 21.47% to $2.6 million in 2024, then grew by 2.85% to $2.7 million in 2025, then fell by 3.81% to $2.6 million in 2026.
• Business Quant data shows NAGE's Non-Current Deffered Revenue at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.